Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;328:849-850 (10 April), doi:10.1136/bmj.328.7444.849
Heralds a new era in the treatment of primary hyperparathyroidism
| The first 150 words of the full text of this article appear below. |
Primary hyperparathyroidism is a more prevalent condition than many perceive. The overall incidence is 25 per 100 000 of the United Kingdom's population.1 However, in women over the age of 45 it may affect one in 500, and more than 1% of post-menopausal women have raised serum concentrations of calcium.2 Parathyroidectomy is the treatment of choice in symptomatic primary hyperparathyroidism. It cures fatigue and the bone, abdominal, urological, and mental symptoms associated with hypercalcaemia. Parathyroidectomy also results in a quantifiable improvement in health related quality of life.3 Additionally a 25 year follow up of patients with untreated "asymptomatic disease" showed a notable increase in cardiovascular deaths compared with age matched normocalcaemic controls.2 Support for an operative approach is further provided by lack of an effective medical treatment and the cost and doctor hours involved in the follow up of conservatively managed patients.
Traditionally parathyroidectomy involves a collar incision, bilateral exploration
F Fausto Palazzo, specialist registrar in endocrine surgery, Gregory P Sadler, consultant endocrine surgeon
Department of Endocrine Surgery, John Radcliffe Hospital, Oxford OX3 9DU
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+